181 related articles for article (PubMed ID: 16314433)
41. Bone marrow allograft rejection mediated by a novel murine NK receptor, NKG2I.
Koike J; Wakao H; Ishizuka Y; Sato TA; Hamaoki M; Seino K; Koseki H; Nakayama T; Taniguchi M
J Exp Med; 2004 Jan; 199(1):137-44. PubMed ID: 14707119
[TBL] [Abstract][Full Text] [Related]
42. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
Guo KY; Mei JZ; Yao KT
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
[TBL] [Abstract][Full Text] [Related]
43. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
44. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
45. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
46. The innate immune response to tumors and its role in the induction of T-cell immunity.
Diefenbach A; Raulet DH
Immunol Rev; 2002 Oct; 188():9-21. PubMed ID: 12445277
[TBL] [Abstract][Full Text] [Related]
47. NKG2D is critical for NK cell activation in host defense against Pseudomonas aeruginosa respiratory infection.
Wesselkamper SC; Eppert BL; Motz GT; Lau GW; Hassett DJ; Borchers MT
J Immunol; 2008 Oct; 181(8):5481-9. PubMed ID: 18832705
[TBL] [Abstract][Full Text] [Related]
48. NKG2D and Related Immunoreceptors.
Strong RK; McFarland BJ
Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
[TBL] [Abstract][Full Text] [Related]
49. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
50. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy.
Park MJ; Bae JH; Chung JS; Kim SH; Kang CD
Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289
[TBL] [Abstract][Full Text] [Related]
51. Cancer immunosurveillance: NKG2D breaks cover.
Ljunggren HG
Immunity; 2008 Apr; 28(4):492-4. PubMed ID: 18400193
[TBL] [Abstract][Full Text] [Related]
52. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo.
Cook JL; Miura TA; Iklé DN; Lewis AM; Routes JM
Cancer Res; 2003 Jun; 63(12):3435-43. PubMed ID: 12810682
[TBL] [Abstract][Full Text] [Related]
53. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.
Arina A; Murillo O; Hervás-Stubbs S; Azpilikueta A; Dubrot J; Tirapu I; Huarte E; Alfaro C; Pérez-Gracia JL; González-Aseguinolaza G; Sarobe P; Lasarte JJ; Jamieson A; Prieto J; Raulet DH; Melero I
Int J Cancer; 2007 Sep; 121(6):1282-95. PubMed ID: 17520674
[TBL] [Abstract][Full Text] [Related]
54. Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand.
Nakamura K; Nakayama M; Kawano M; Amagai R; Ishii T; Harigae H; Ogasawara K
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9421-6. PubMed ID: 23690625
[TBL] [Abstract][Full Text] [Related]
55. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.
Cerwenka A; Bakker AB; McClanahan T; Wagner J; Wu J; Phillips JH; Lanier LL
Immunity; 2000 Jun; 12(6):721-7. PubMed ID: 10894171
[TBL] [Abstract][Full Text] [Related]
56. Possible role of arginase-1 in concomitant tumor immunity.
Korrer MJ; Zhang Y; Routes JM
PLoS One; 2014; 9(3):e91370. PubMed ID: 24614600
[TBL] [Abstract][Full Text] [Related]
57. Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells.
Ogbomo H; Michaelis M; Klassert D; Doerr HW; Cinatl J
Neoplasia; 2008 Dec; 10(12):1402-10. PubMed ID: 19048119
[TBL] [Abstract][Full Text] [Related]
58. Cutting edge: the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1epsilon.
Nausch N; Florin L; Hartenstein B; Angel P; Schorpp-Kistner M; Cerwenka A
J Immunol; 2006 Jan; 176(1):7-11. PubMed ID: 16365389
[TBL] [Abstract][Full Text] [Related]
59. E1A oncogene induced sensitization to NK cell induced apoptosis requires PIDD and Caspase-2.
Radke JR; Routes JM; Cook JL
Cell Death Discov; 2019; 5():110. PubMed ID: 31285853
[TBL] [Abstract][Full Text] [Related]
60. Identification of the rat NKG2D ligands, RAE1L and RRLT, and their role in allograft rejection.
Zhuo M; Fujiki M; Wang M; Piard-Ruster K; Wai LE; Wei L; Martinez OM; Krams SM
Eur J Immunol; 2010 Jun; 40(6):1748-57. PubMed ID: 20306467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
